A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years

Rheumatology International

Volumn 33, Issue 9, 2013, Pages 2231-2239

  Audran, M ^a   Jakob, F J ^b   Palacios, S ^c   Brandi, M L ^d   Broll H ^e   Hamdy, N A T ^f   McCloskey, E V ^g  

^a UNIV Angers   (France)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c Instituto Palacios de Salud Y Medicina de la Mujer   (Spain)

^d Policlinico Careggi   (Italy)

^e Rheuma Ambulatorium Wien Oberlaa   (Austria)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Adherence; Observational survey; Osteoporosis; Safety; Strontium ranelate

Indexed keywords

STRONTIUM RANELATE;

ADULT; AGED; ARTICLE; BODY MASS; COHORT ANALYSIS; CONSULTATION; DRUG SAFETY; FEMALE; FEMUR NECK; FOLLOW UP; FRAGILITY FRACTURE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MEDICATION COMPLIANCE; OBSERVATIONAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGISTER; RISK FACTOR; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; THIOPHENES;

EID: 84883138416     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-012-2594-y     Document Type: Article

References (28)

1. Bliuc D, Nguyen ND, Milch VE et al (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513-521
2. International Osteoporosis Foundation (2012) Facts and statistics about osteoporosis and its implications. Available at: www.iofbonehealth.org/facts- and-statistics.html. Accessed 30 Jan 2012
3. Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010-2018
4. Siris ES, Miller PD, Barrett-Connor E et al (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the national osteoporosis risk assessment. JAMA 286:2815-2822
5. Kanis JA, Burlet N, Cooper C et al (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399-428
6. Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459-468
7. Reginster JY, Seeman E, De Vernejoul MC et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816-2822
8. Reginster J-Y, Felsenberg D, Boonen S et al (2008) Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 58:1687-1695
9. European Medicines Agency (2009) Strontium ranelate. Summary of product characteristics. Available at: http://www.ema.europa.eu. Accessed 30 Jan 2012
10. Cummings SR, Eckert S, Krueger KA et al (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 281:2189-2197
11. Barrett-Connor E, Mosca L, Collins P et al (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125-137
12. Jick H, Derby LE, Myers MW et al (1996) Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 348:981-983
13. Vickers MR, MacLennan AH, Lawton B et al (2007) Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 335:239
14. Breart G, Cooper C, Meyer O et al (2010) Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK general practice research database. Osteoporos Int 21:1181-1187
15. Landfeldt E, Strom O, Robbins S et al (2012) Adherence to treatment of primary osteoporosis and its association to fractures-the Swedish adherence register analysis (SARA). Osteoporos Int 23:433-443
16. Cotte FE, Fardellone P, Mercier F et al (2010) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21:145-155
17. Freemantle N, Cooper C, Roux C et al (2010) Baseline observations from the POSSIBLE EU(R) study: characteristics of postmenopausal women receiving bone loss medications. Arch Osteoporos 5:61-72
18. Barrett-Connor E, Ensrud K, Tosteson AN et al (2009) Design of the POSSIBLE US trade mark study: postmenopausal women's compliance and persistence with osteoporosis medications. Osteoporos Int 20:463-472
19. Blotman F, Cortet B, Hilliquin P et al (2007) Characterisation of patients with postmenopausal osteoporosis in French primary healthcare. Drugs Aging 24:603-614
20. Silverman SL (2010) Osteoporosis therapies: evidence from health-care databases and observational population studies. Calcif Tissue Int 87:375-384
21. Vandenbroucke JP (2011) Why do the results of randomised and observational studies differ? BMJ 343:d7020
22. Rabenda V, Reginster JY (2010) Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures. Osteoporos Int 21:1993-2002
23. Rabenda V, Hiligsmann M, Reginster JY (2009) Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother 10:2303-2315
24. Papaioannou A, Kennedy CC, Dolovich L et al (2007) Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 24:37-55
25. Papaioannou A, Ioannidis G, Adachi JD et al (2003) Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14:808-813
26. Osborne V, Layton D, Perrio M et al (2010) Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England. Drug Saf 33:579-591
27. Oger E (2000) Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 83:657-660
28. Musette P, Brandi ML, Cacoub P et al (2010) Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporos Int 21:723-732